Key result
Rofecoxib use was associated with an increased risk of myocardial infarction or ischemic stroke (RR 1.15; 95% CI 1.06-1.25), whereas naproxen use was associated with a decreased risk (RR 0.75).
Why the study?
Does the use of coxibs or nonselective NSAIDs increase the risk of myocardial infarction or ischemic stroke in Medicare beneficiaries?
Cohort (n=98,370)
Does the use of coxibs or nonselective NSAIDs increase the risk of myocardial infarction or ischemic stroke in Medicare beneficiaries?
Relative Risk: 1.15 (95% CI 1.06–1.25)
In a large cohort of Medicare beneficiaries, rofecoxib use was associated with an early and persistent increased risk of cardiovascular events, whereas naproxen was associated with a decreased risk.
No takes yet. Share an insight, caveat, or question.
Rofecoxib warrants caution in arthritis patients; this cohort study leaves open differential NSAID effects for randomized confirmation.
Solomon et al. (2006) conducted a cohort in Cardiovascular risk in new users of NSAIDs and coxibs (n=98,370). Coxibs and NSAIDs vs. Patients who did not use NSAIDs or coxibs, but started other medications unrelated to cardiovascular risk was evaluated on Hospital admission for either myocardial infarction or ischemic stroke (RR 1.15, 95% CI 1.06-1.25). Rofecoxib use was associated with an increased risk of myocardial infarction or ischemic stroke (RR 1.15; 95% CI 1.06-1.25), whereas naproxen use was associated with a decreased risk (RR 0.75).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: